Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Wavelength Fluorescence Imaging Using Fluorescently Labelled Adalimumab and Risankizumab for Visualizing Drug Targeting in Inflammatory Bowel Diseases

NCT07258641 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT07258641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07258641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Wavelength Fluorescence Imaging Using Fluorescently Labelled Adalimumab and Risankizumab for Visualizing Drug Targeting in Inflammatory Bowel Diseases
Lead sponsor
University Medical Center Groningen
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 15, 2026
Completion date
April 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd), ulcerative colitis (uc)